Company news

Aura Biosciences, Inc. news in 2024

Aura Biosciences, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference

November 25, 2024

Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights

November 11, 2024

Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial

October 16, 2024

Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma

September 11, 2024

Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024

September 2, 2024

Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting

August 25, 2024

Aura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights

August 7, 2024

Aura Biosciences to Participate in the Jefferies Global Healthcare Conference

May 29, 2024

Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024

May 22, 2024

Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights

May 8, 2024

Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

March 26, 2024

Decks in 2024